How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pneumonia-due-to-staphylococcus-aureus.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pneumonia due to Staphylococcus aureus — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pneumonia due to Staphylococcus aureus (disease) competitive landscape: 9 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

9 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pneumonia due to Staphylococcus aureus, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Xenleta	LEFAMULIN	Hong Kong	Pleuromutilin Antibacterial		2019-01-01
Teflaro	CEFTAROLINE FOSAMIL	AbbVie	Cephalosporin Antibacterial		2010-01-01
Vibativ	TELAVANCIN	Cumberland	Lipoglycopeptide Antibacterial		2009-01-01
Vibativ	TELAVANCIN HYDROCHLORIDE	Cumberland	Lipoglycopeptide Antibacterial		2009-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Augmentin 250	CLAVULANIC ACID	Dr Reddys Labs Inc	beta Lactamase Inhibitor		1984-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Amoxicilli	Amoxicilli	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C
Amoxycillin	Amoxycillin	King George's Medical University		5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Cumberland · 2 drugs in Pneumonia due to Staphylococcus aureus
Dr Reddys Labs Inc · 1 drug in Pneumonia due to Staphylococcus aureus
Generic (originally Beecham/GSK) · 1 drug in Pneumonia due to Staphylococcus aureus
Hong Kong · 1 drug in Pneumonia due to Staphylococcus aureus
King George's Medical University · 1 drug in Pneumonia due to Staphylococcus aureus
Pfizer Inc. · 1 drug in Pneumonia due to Staphylococcus aureus
AbbVie · 1 drug in Pneumonia due to Staphylococcus aureus
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Pneumonia due to Staphylococcus aureus

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pneumonia due to Staphylococcus aureus:

Cite this brief

Drug Landscape (2026). Pneumonia due to Staphylococcus aureus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumonia-due-to-staphylococcus-aureus. Accessed 2026-06-10.

Pneumonia due to Staphylococcus aureus full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing